Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

NCT04498741 is registered in ClinicalTrials.gov with Enanta Pharmaceuticals, Inc as lead sponsor.

NCT NCT04498741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
Lead sponsor
Enanta Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2020
Completion date
June 1, 2021
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rsv infection